^
BIOMARKER:
MET overexpression
i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET overexpression
NSCLC
SCC244
Sensitive
:
C2
MET overexpression
NSCLC
erlotinib + ARQ 197
Sensitive
:
C3
MET overexpression
Gastric Cancer
ARQ 197
Sensitive
:
C3
MET overexpression
Melanoma
vemurafenib
Resistant
:
C3
MET overexpression
CRC
EGFR inhibitor
Resistant
:
C3
MET overexpression
GBM
bevacizumab
Resistant
:
C3
MET overexpression
HCC
tepotinib
Sensitive
:
C3
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive
:
C3
MET overexpression
Pancreatic Cancer
cetuximab
Resistant
:
C4
MET overexpression
Pancreatic Cancer
trametinib + dabrafenib
Resistant
:
C4
MET overexpression
Pancreatic Cancer
TR1801-ADC
Sensitive
:
D
MET overexpression
Adrenal Cortex Carcinoma
cabozantinib capsule
Sensitive
:
D
MET overexpression
LUAD
CKD-702
Sensitive
:
D
MET overexpression
Melanoma
BRAF inhibitor + MEK inhibitor
Resistant
:
D
MET overexpression
HCC
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
tepotinib
Sensitive
:
D
MET overexpression
NSCLC
crizotinib + chidamide
Sensitive
:
D
MET overexpression
NSCLC
MG132
Sensitive
:
D
MET overexpression
Gastric Cancer
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
Sym015
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our